Abstract

The mission of the Gene Transfer and Somatic Cell Engineering (GTSC) Core is to develop, validate, and supply cell-based experimental products for Phase I and II clinical trials so that investigators can evaluate their safety and potential clinical benefit. In 2014, the GTSC Core moved to the Cell Therapy and Cell Engineering Facility (CTCEF), which opened when the Zuckerman II building was opened.
The aims of the GTSC Core have not changed. The Core supports the implementation of Phase I/II clinical trials based on cell engineering and adoptive cell therapies.
Its aims are as follows:
AIM1 : To develop SOPs and batch records for cell processing and engineering, vector production.
AIM2 : GMP manufacturing: Patient cell (expansion, purification, transduction, formulation); Vector stocks (plasmid DNA, cell banks).
AIM3 : Biosafety/release testing: Patient cells and vector stocks (e.g., phenotype, potency, purity, stability); Gene transfer/expression.
AIM4 : To monitor patients? samples post-infusion (e.g., FACS, Q-PCR).
AIM5 : To provide technological and regulatory expertise (GXP, FDA, RAC-NIH).

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-55
Application #
10084821
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-20
Project End
2023-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
55
Fiscal Year
2021
Total Cost
Indirect Cost

  Institution

Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065

  Publications

Haxaire, Coline; Hakobyan, Narine; Pannellini, Tania et al. (2018) Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-? pathway. Blood 132:1064-1074
Parker, Patricia A; Banerjee, Smita C; Matasar, Matthew J et al. (2018) Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: A cluster randomized controlled trial. Cancer 124:4567-4576
Chou, Chun; Li, Ming O (2018) Re(de)fining Innate Lymphocyte Lineages in the Face of Cancer. Cancer Immunol Res 6:372-377
Scope, A; Dusza, S W; Pellacani, G et al. (2018) Accuracy of tele-consultation on management decisions of lesions suspect for melanoma using reflectance confocal microscopy as a stand-alone diagnostic tool. J Eur Acad Dermatol Venereol :
Baradaran, Rozbeh; Wang, Chongyuan; Siliciano, Andrew Francis et al. (2018) Cryo-EM structures of fungal and metazoan mitochondrial calcium uniporters. Nature 559:580-584
Patel, Sunil V; Yu, David; Elsolh, Basheer et al. (2018) Assessment of Conflicts of Interest in Robotic Surgical Studies: Validating Author's Declarations With the Open Payments Database. Ann Surg 268:86-92
Wolner, Z J; Marghoob, A A; Pulitzer, M P et al. (2018) A case report of disappearing pigmented skin lesions associated with pembrolizumab treatment for metastatic melanoma. Br J Dermatol 178:265-269
Corrias, Giuseppe; Monti, Serena; Mannelli, Lorenzo (2018) Right Upper Quadrant Pain in a 47-Year-Old Woman. Gastroenterology 154:e11-e12
Hu, Zishuo I; Shia, Jinru; Stadler, Zsofia K et al. (2018) Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clin Cancer Res 24:1326-1336
Connors, Joseph M; Jurczak, Wojciech; Straus, David J et al. (2018) Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma. N Engl J Med 378:331-344

Showing the most recent 10 out of 8799 publications